DCM
SLXP

Decatur Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Decatur Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-45,225
Closed -$5.58M – 109
2014
Q2 		$5.58M Sell
45,225
-11,700
-21% -$1.29M 1.05% 44
2014
Q1 		$5.9M Buy
+56,925
New +$5.83M 1.12% 42

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Decatur Capital Management's SLXP Position: Q3 2014 in Review

Decatur Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 45,225 shares — an estimated $5.58M sold.

Decatur Capital Management first reported a position in SLXP in Q1 2014 and held it in 2 quarters. The position peaked at $5.9M in Q1 2014. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Decatur Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Decatur Capital Management sold 45,225 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $5.58M.
  • Decatur Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 2 quarters.
  • Decatur Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $5.9M in Q1 2014.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Decatur Capital Management's 13F filing for Q3 2014, filed 7 Nov 2014.